Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access

In filings with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Johnson & Johnson, Merck, Pfizer, and Regeneron, activist shareholders at the Interfaith Center on Corporate Responsibility (ICCR) are asking companies to weigh patient access when they're developing patent strategies.